IASLC: The Lung Ambition Alliance will amplify initiatives in lung cancer on a global scale

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The founding partners of the Lung Ambition Alliance launched the group July 8 with the primary objective of doubling five-year survival rates for patients with lung cancer—up to 40%.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong

YOU MAY BE INTERESTED IN

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening. 
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login